Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Arch Surg ; 131(2): 160-5, 1996 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8611072

RESUMEN

OBJECTIVE: To determine the efficacy and relative effectiveness of conjugated entrogens (CE) and fresh-frozen plasma (FFP) in normalizing prolonged preoperative bleeding times during renal transplantation. DESIGN: Prospective, randomized trial. SETTING: A university regional referral center for transplantation. PATIENTS: Patients scheduled for renal transplantation with preoperative bleeding times greater than 10 minutes (normal, < 7 minutes) following informed consent were asked to participate in the randomized protocol. Those with bleeding times of 8 to 9.5 minutes were asked, following informed consent, to be a control group receiving neither CE nor FFP. INTERVENTIONS: Following induction of anesthesia and drawing of baseline laboratory tests, patients were administered randomly, using a table of random numbers, either 50 mg of CE or 2 U of FFP. MAIN OUTCOME MEASURES: Bleeding time measurements and other laboratory tests were repeated at the end of surgery as well as at 24 and 48 hours postoperatively. RESULTS: Treatment with CE and FFP decreased the patients' bleeding times from 16.68 +/- 0.8 (SEM) and 17.13 +/- 0.85 minutes to 7.67 +/- 0.79 (P < .001) and 10.50 +/- 1.27 minutes (P < .001), respectively, by the end of surgery. At 24 and 48 hours postoperatively, the CE group had bleeding times of 9.77 +/- 0.99 and 9.81 +/- 1.24 minutes (P < .001 for both), respectively, whereas the FFP group bleeding times were 12.76 +/- 1.57 (P = .003) and 12.14 +/- 1.56 minutes (P = .001), respectively. There were no statistical differences for the control group compared with baseline either at the end of surgery or at 24 hours. CONCLUSIONS: Although both CE and FFP significantly decreased prolonged preoperative bleeding times during renal transplantation, CE might be preferred because of lower risk and cost, as well as a longer duration of action.


Asunto(s)
Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/terapia , Coagulantes/uso terapéutico , Estrógenos Conjugados (USP)/uso terapéutico , Trasplante de Riñón , Plasma , Adulto , Pruebas de Coagulación Sanguínea , Transfusión Sanguínea , Coagulantes/administración & dosificación , Coagulantes/economía , Costos de los Medicamentos , Estrógenos Conjugados (USP)/administración & dosificación , Estrógenos Conjugados (USP)/economía , Humanos , Consentimiento Informado , Cuidados Posoperatorios , Cuidados Preoperatorios , Estudios Prospectivos , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento
6.
7.
Chest ; 101(3): 884, 1992 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-1541178
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA